Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.
Li T, Guo J, Liu Y, Du Z, Guo Z, Fan Y, Cheng L, Zhang Y, Gao X, Zhao Y, He X, Wu W, Gao N, Wu Y, Li J, Zhang Y, Kang W, Cai Z, Wang W, Li X, Zan Y, Nguyen MH, Ji F.
Li T, et al.
Cancer Immunol Immunother. 2023 Jul;72(7):2137-2149. doi: 10.1007/s00262-023-03404-8. Epub 2023 Feb 25.
Cancer Immunol Immunother. 2023.
PMID: 36840762
Free PMC article.